• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Targeting Cytokines in Inflammatory Bowel Disease.靶向炎症性肠病中的细胞因子
Gastroenterol Hepatol (N Y). 2023 Sep;19(9):550-552.
2
[The cytokines in inflammatory bowel disease].[炎症性肠病中的细胞因子]
Postepy Hig Med Dosw (Online). 2009 Aug 18;63:389-94.
3
Targeting cytokines in inflammatory bowel disease.针对炎症性肠病中的细胞因子
Sci Transl Med. 2022 Dec 14;14(675):eabq4473. doi: 10.1126/scitranslmed.abq4473.
4
Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease.最新进展：细胞因子失衡在炎症性肠病发病机制中的作用
Mediators Inflamm. 2017;2017:4810258. doi: 10.1155/2017/4810258. Epub 2017 Mar 21.
5
Cytokines in inflammatory bowel disease.炎症性肠病中的细胞因子
Rom J Intern Med. 2015 Apr-Jun;53(2):118-27. doi: 10.1515/rjim-2015-0016.
6
ROS Scavenging and inflammation-directed polydopamine nanoparticles regulate gut immunity and flora therapy in inflammatory bowel disease.ROS 清除和炎症靶向聚多巴胺纳米颗粒调节炎症性肠病中的肠道免疫和菌群治疗。
Acta Biomater. 2023 Apr 15;161:250-264. doi: 10.1016/j.actbio.2023.02.026. Epub 2023 Mar 1.
7
Immune system alterations in patients with inflammatory bowel disease during remission.炎症性肠病缓解期患者的免疫系统改变
Medicina (Kaunas). 2008;44(1):27-33.
8
Role of cytokines and platelet-activating factor in inflammatory bowel disease. Implications for therapy.细胞因子和血小板活化因子在炎症性肠病中的作用。对治疗的启示。
Dis Colon Rectum. 1996 Feb;39(2):217-23. doi: 10.1007/BF02068079.
9
Current concept of the role of monocytes/macrophages in inflammatory bowel disease--balance of proinflammatory and immunosuppressive mediators.单核细胞/巨噬细胞在炎症性肠病中作用的当前概念——促炎介质与免疫抑制介质的平衡
Ital J Gastroenterol Hepatol. 1998 Jun;30(3):338-44.
10
Soluble ligands as drug targets for treatment of inflammatory bowel disease.可溶性配体作为治疗炎症性肠病的药物靶点。
Pharmacol Ther. 2021 Oct;226:107859. doi: 10.1016/j.pharmthera.2021.107859. Epub 2021 Apr 23.

引用本文的文献

1
Modulation of Orosomucoid-like Protein 3 Activity in the Management of Inflammatory Bowel Disease.类orosomucoid蛋白3活性调节在炎症性肠病治疗中的作用
J Biotechnol Biomed. 2024;7(4):433-444. doi: 10.26502/jbb.2642-91280167. Epub 2024 Oct 18.

本文引用的文献

1
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.美沙拉嗪诱导和维持治疗溃疡性结肠炎的疗效。
N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940.
2
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.埃特拉莫德用于溃疡性结肠炎的诱导和维持治疗（ELEVATE）：两项随机、双盲、安慰剂对照的3期研究。
Lancet. 2023 Apr 8;401(10383):1159-1171. doi: 10.1016/S0140-6736(23)00061-2. Epub 2023 Mar 2.
3
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.利斯利珠单抗作为中重度活动期克罗恩病的维持治疗：来自多中心、随机、双盲、安慰剂对照、撤药期 3 期 FORTIFY 维持试验的结果。
Lancet. 2022 May 28;399(10340):2031-2046. doi: 10.1016/S0140-6736(22)00466-4.
4
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.瑞莎珠单抗诱导治疗克罗恩病的疗效：来自 ADVANCE 和 MOTIVATE 诱导期 3 期临床试验的结果。
Lancet. 2022 May 28;399(10340):2015-2030. doi: 10.1016/S0140-6736(22)00467-6.
5
Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs.通过标志性细胞因子中心重塑免疫介导的炎症性疾病
N Engl J Med. 2021 Aug 12;385(7):628-639. doi: 10.1056/NEJMra1909094.

Targeting Cytokines in Inflammatory Bowel Disease.

作者信息

Dubinsky Marla

机构信息

Professor of Pediatrics and Medicine Co-Director, Susan and Leonard Feinstein IBD Clinical Center Icahn School of Medicine at Mount Sinai New York, New York.

出版信息

Gastroenterol Hepatol (N Y). 2023 Sep;19(9):550-552.

PMID:37771797
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10524412/
Abstract
摘要